<DOC>
	<DOCNO>NCT00004866</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DX-8951f treat woman advance recurrent cancer cervix .</brief_summary>
	<brief_title>DX-8951f Treating Women Who Have Advanced Recurrent Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity DX-8951f woman advance recurrent squamous cell carcinoma cervix . - Evaluate quantitative qualitative toxic effect regimen patient . - Evaluate pharmacokinetics regimen patient . OUTLINE : This multicenter study . Patients receive DX-8951f IV 30 minute daily 5 day . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 37 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced recurrent squamous cell carcinoma cervix curable surgery radiotherapy Measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No malignancy within past 5 year except nonmelanomatous skin cancer No life threaten illness No psychosis , mental disability , incompetence PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : At least 4 week since prior chemotherapy No 1 prior chemotherapy regimen ( except chemotherapy radiosensitization ) No prior camptothecin No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior surgery No concurrent surgery Other : At least 4 week since prior investigational drug ( include analgesic antiemetic ) No concurrent investigational drug within 28 day final dose study drug No concurrent drug induce inhibit CYP3A enzyme</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IV cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>